首页 | 本学科首页   官方微博 | 高级检索  
检索        


Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature
Institution:1. Unit of General Surgery, Campus Bio-Medico University of Rome, Italy;2. Department of Pathology, Campus Bio-Medico University of Rome, Italy;3. Unit of Medical Oncology, Campus Bio-Medico University of Rome, Italy;1. D’ Surgical Department, G. Papanikolaou Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece;2. Division of Transplantation, Department of Surgery, Hippokration Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece;1. The Kinghorn Cancer Centre, 370 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia;2. The Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia;3. NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia;4. Cancer Care Centre, St. George Hospital, Kogarah, NSW, Australia;5. St. Vincents''s Clinical School, Faculty of Medicine, University of NSW, Australia;6. Department of Medical Oncology, Chris O’Brien Lifehouse, Sydney, NSW 2050, Australia;7. Department of Surgery, Bankstown Hospital, Eldridge Road, Bankstown, Sydney, NSW 2200, Australia;8. South Western Sydney Clinical School, Faculty of Medicine, University of NSW, Liverpool, NSW 2170, Australia;9. Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow G61 1BD, Scotland, UK;10. West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, Scotland G4 0SF, UK;11. Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia;12. ANU Medical School, Australian National University, Acton, ACT, Australia;1. Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, D-81377 Munich, Germany;2. Institute of Pathology, Ludwig-Maximilians-University of Munich, D-81377 Munich, Germany;3. Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, D-81377 Munich, Germany;4. Department of General, Abdominal and Vascular Surgery, Otto-von-Guericke-University, D-39120 Magdeburg, Germany;5. Department of Radiation Oncology, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, D-81377 Munich, Germany;6. Department of Molecular Radiation Oncology, Deutsches Krebsforschungszentrum (DKFZ), D-69120 Heidelberg, Germany
Abstract:Neoadjuvant treatments (chemo or chemoradiation therapy) are used for patients with locally advanced Pancreatic Ductal Adeno-Carcinoma (PDAC). FOLFIRINOX is now considered an effective treatment modality for patients with metastatic pancreatic cancer and a promising option for patients with locally advanced PDAC. Complete pathologic response after neoadjuvant therapies is anecdotic and its prognostic impact is completely unclear. We report the case of a complete pathological response after treatment with FOLFIRINOX in a patient affected by a locally advanced PDAC with a review of the literature regarding the use of FOLFIRINOX for locally advanced PDAC.
Keywords:FOLFIRINOX  Pancreatic cancer  Neoadjuvant treatment  Complete pathological response  Locally advanced pancreatic cancer  Neoadjuvant chemotherapy
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号